Table 1 Summary of clinicopathological features of FA-DLBCL reported cases and our case
Author | Cases | Age | Sex | Location | Diagnosis | Phenotype | EBV latency | Stage | Adjuvant treatment | Follow-up (months) |
|---|---|---|---|---|---|---|---|---|---|---|
Garces et al, 2019 [7] | 1 | 50 | M | Left atrial myxoma | FA-DLBCL | Non-GC | NA | Localized | None | 65-WER |
Zanelli et al, 2019 [8] | 1 | 75 | F | Adrenal pseudocyst | FA-DLBCL | Non-GC | NA | NA | NA | NA |
Boyer et al, 2017 [4] | 12 | 54 | F | Left atrial myxoma | FA-DLBCL | NA | NA | NA | NA | 130-WER |
55 | F | Left atrial myxoma | FA-DLBCL | Non-GC | Type III | NA | None | Died 2 mo-WER | ||
54 | M | Left atrial myxoma | FA-DLBCL | Non-GC | Type III | Localized | None | Died 26 mo-recurrent atrial mass | ||
56 | M | Aortic aneurysm | FA-DLBCL | Non-GC | Type III | Localized | R-CHOP × 6 | 24-persistent local disease | ||
68 | M | Arterial thromboembolism | FA-DLBCL | Non-GC | Type III | NA | R-COEP × 2 | Died 10 mo-WER | ||
71 | M | Aortobifemoral prosthesis | FA-DLBCL | Non-GC | Type II-III | NA | None | 10-WER | ||
79 | M | Testicular hematoma | FA-DLBCL | Non-GC | Type III | NA | None | Died 17 mo-WER | ||
25 | M | Subdural hematoma | FA-DLBCL | Non-GC | Type II-III | Localized | None | 7-WER | ||
37 | F | Splenic pseudocyst | FA-DLBCL | Non-GC | NA | Localized | R-CHOP × 3 | 32-WER | ||
73 | M | Retroperitoneal pseudocyst | FA-DLBCL | Non-GC | NA | Localized | R-CHOP × 6 | 43-WER | ||
70 | M | Adrenal pseudocyst | FA-DLBCL | Non-GC | Type III | Localized | None | 14-WER | ||
44 | M | Retroperitoneal pseudocyst | FA-DLBCL | Non-GC | Type III | Localized | CHOP × 5 | 84-WER | ||
Kirschenbaum et al, 2017 [5] | 1 | 81 | M | Arachnoid cyst | FA-DLBCL | NA | NA | Localized | R-L x NA | NA |
Yan et al, 2017 | 4 | 46 | F | Left atrial myxoma | DLBCL-CI | Non-GC | Type III | Localized | None | 10-WER |
61 | F | Left atrial myxoma | DLBCL-CI | GC | Type III | Localized | None | 7-WER | ||
54 | M | Left atrial myxoma | DLBCL-CI | Non-GC | Type III | Localized | None | 7-WER | ||
46 | F | Left atrial myxoma | DLBCL-CI | Non-GC | Type III | Localized | None | 3-WER | ||
Aguilar et al, 2015 [1] | 1 | 52 | M | Left atrial myxoma | FA-DLBCL | Non-GC | Type III | Localized | None | 42-WER |
Tapan et al, 2015 [6] | 1 | 49 | M | Left atrial myxoma | EBV-DLBCL | Non-GC | Type III | Localized | R-CHOP × 6 | 12-WER |
Gruver et a., 2012 [2] | 3 | 55 | M | Aortic root graft | FA-DLBCL | Non-GC | Type III | Localized | R-CEOP × 8 | 16-WER |
56 | M | Left atrium | FA-DLBCL | Non-GC | Type III | Localized | R-CHOP × 6 | 8-WER | ||
75 | M | Mitral valve | FA-DLBCL | Non-GC | EBV - | Localized | R-CVP × 1 and R-CHOP × 6 | 39-WER | ||
Svec et al, 2012 [4] | 1 | 60 | F | Left atrial myxoma | EBV-DLBCL | Non-GC | Type III | Localized | R-CHOP × 6 | 7-WER |
Loong et al, 2010 [3] | 4 | 29 | M | Splenic cyst | DLBCL-CI | Non-GC | Type III | Localized | Rituximab × 6 | 6-WER |
88 | M | Right hydrocele | DLBCL-CI | Non-GC | Type III | NA | Lost to follow-up | NA | ||
70 | F | Left atrial myxoma | DLBCL-CI | Non-GC | Type III | Localized | R-CEOP × 4 | Died 5 mo-WER | ||
78 | M | Knee prosthesis | DLBCL-CI | Non-GC | Type III | Localized | RT × 7 | 84 (7 y)-WER | ||
Present case | 1 | 57 | F | Left atrial myxoma | Plasmacytic FA-DLBCL | Non-GC | Type I | NA | None | 1-Loss of follow-up |